{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:27:01Z","timestamp":1771676821558,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T00:00:00Z","timestamp":1560470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1385-z","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T08:02:52Z","timestamp":1560499372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2752-9735","authenticated-orcid":false,"given":"Kasia A.","family":"Sablik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian C.","family":"Clahsen-van Groningen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caspar W. N.","family":"Looman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Damman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelon","family":"van Agteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel G. H.","family":"Betjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,14]]},"reference":[{"issue":"7","key":"1385_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","volume":"63","author":"JD Pirsch","year":"1997","unstructured":"Pirsch JD, Miller J, Deierhoi MH, Vincenti F. Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 kidney transplant study group. Transplantation. 1997;63(7):977\u201383.","journal-title":"Transplantation."},{"issue":"3","key":"1385_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJM198401193100303","volume":"310","author":"RM Merion","year":"1984","unstructured":"Merion RM, White DJ, Thiru S, Evans DB, Calne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med. 1984;310(3):148\u201354.","journal-title":"N Engl J Med"},{"issue":"18","key":"1385_CR3","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.2165\/00003495-200767180-00003","volume":"67","author":"G Ciancio","year":"2007","unstructured":"Ciancio G, Burke GW, Miller J. Induction therapy in renal transplantation : an overview of current developments. Drugs. 2007;67(18):2667\u201380.","journal-title":"Drugs."},{"issue":"3","key":"1385_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","volume":"11","author":"KE Lamb","year":"2011","unstructured":"Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11(3):450\u201362.","journal-title":"Am J Transplant"},{"issue":"6","key":"1385_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1432-2277.2012.01453.x","volume":"25","author":"T Fehr","year":"2012","unstructured":"Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012;25(6):623\u201332.","journal-title":"Transpl Int"},{"issue":"12","key":"1385_CR6","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/j.1432-2277.2011.01309.x","volume":"24","author":"G Bartel","year":"2011","unstructured":"Bartel G, Schwaiger E, Bohmig GA. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int. 2011;24(12):1142\u201355.","journal-title":"Transpl Int"},{"issue":"3","key":"1385_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1600-6143.2007.02104.x","volume":"8","author":"FG Cosio","year":"2008","unstructured":"Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant. 2008;8(3):492\u20136.","journal-title":"Am J Transplant"},{"issue":"1","key":"1385_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","volume":"90","author":"RS Gaston","year":"2010","unstructured":"Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68\u201374.","journal-title":"Transplantation."},{"issue":"4","key":"1385_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","volume":"77","author":"RR Redfield","year":"2016","unstructured":"Redfield RR, Ellis TM, Zhong W, Scalea JR, Zens TJ, Mandelbrot D, et al. Current outcomes of chronic active antibody mediated rejection - a large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol. 2016;77(4):346\u201352.","journal-title":"Hum Immunol"},{"issue":"9","key":"1385_CR10","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/j.1600-6143.2007.01895.x","volume":"7","author":"JM Gloor","year":"2007","unstructured":"Gloor JM, Sethi S, Stegall MD, Park WD, Moore SB, DeGoey S, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant. 2007;7(9):2124\u201332.","journal-title":"Am J Transplant"},{"issue":"7","key":"1385_CR11","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1600-6143.2007.01836.x","volume":"7","author":"B Sis","year":"2007","unstructured":"Sis B, Campbell PM, Mueller T, Hunter C, Cockfield SM, Cruz J, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant. 2007;7(7):1743\u201352.","journal-title":"Am J Transplant"},{"key":"1385_CR12","doi-asserted-by":"crossref","unstructured":"Patri P, Seshan SV, Matignon M, Desvaux D, Lee JR, Lee J, et al. Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int. 2015.","DOI":"10.1038\/ki.2015.288"},{"issue":"7","key":"1385_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1097\/TP.0b013e3181efcffd","volume":"90","author":"R John","year":"2010","unstructured":"John R, Konvalinka A, Tobar A, Kim SJ, Reich HN, Herzenberg AM. Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation. 2010;90(7):757\u201364.","journal-title":"Transplantation."},{"issue":"2\u20133","key":"1385_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.trim.2012.08.005","volume":"27","author":"RN Smith","year":"2012","unstructured":"Smith RN, Malik F, Goes N, Farris AB, Zorn E, Saidman S, et al. Partial therapeutic response to rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol. 2012;27(2\u20133):107\u201313.","journal-title":"Transpl Immunol"},{"key":"1385_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/828732","volume":"2014","author":"GH An","year":"2014","unstructured":"An GH, Yun J, Hong YA, Khvan M, Chung BH, Choi BS, et al. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. J Immunol Res. 2014;2014:828732.","journal-title":"J Immunol Res"},{"issue":"11","key":"1385_CR16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","volume":"25","author":"H Billing","year":"2012","unstructured":"Billing H, Rieger S, Susal C, Waldherr R, Opelz G, Wuhl E, et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int. 2012;25(11):1165\u201373.","journal-title":"Transpl Int"},{"issue":"5","key":"1385_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/ctr.12345","volume":"28","author":"J Kahwaji","year":"2014","unstructured":"Kahwaji J, Najjar R, Kancherla D, Villicana R, Peng A, Jordan S, et al. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab. Clin Transpl. 2014;28(5):546\u201353.","journal-title":"Clin Transpl"},{"issue":"9","key":"1385_CR18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1432-2277.2009.00896.x","volume":"22","author":"L Rostaing","year":"2009","unstructured":"Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int. 2009;22(9):906\u201313.","journal-title":"Transpl Int"},{"issue":"5","key":"1385_CR19","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ctr.12535","volume":"29","author":"T Bachelet","year":"2015","unstructured":"Bachelet T, Nodimar C, Taupin JL, Lepreux S, Moreau K, Morel D, et al. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. Clin Transpl. 2015;29(5):439\u201346.","journal-title":"Clin Transpl"},{"key":"1385_CR20","doi-asserted-by":"crossref","unstructured":"Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A randomized trial of Bortezomib in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2017.","DOI":"10.1681\/ASN.2017070818"},{"issue":"4","key":"1385_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","volume":"8","author":"K Solez","year":"2008","unstructured":"Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753\u201360.","journal-title":"Am J Transplant"},{"issue":"3","key":"1385_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","volume":"10","author":"B Sis","year":"2010","unstructured":"Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10(3):464\u201371.","journal-title":"Am J Transplant"},{"issue":"3","key":"1385_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1600-6143.2011.03926.x","volume":"12","author":"M Mengel","year":"2012","unstructured":"Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12(3):563\u201370.","journal-title":"Am J Transplant"},{"issue":"2","key":"1385_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ajt.12590","volume":"14","author":"M Haas","year":"2014","unstructured":"Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272\u201383.","journal-title":"Am J Transplant"},{"issue":"5","key":"1385_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/ajt.13661","volume":"16","author":"M Haas","year":"2016","unstructured":"Haas M. The revised (2013) Banff classification for antibody-mediated rejection of renal allografts: update, difficulties, and future considerations. Am J Transplant. 2016;16(5):1352\u20137.","journal-title":"Am J Transplant"},{"issue":"6","key":"1385_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461\u201370.","journal-title":"Ann Intern Med"},{"key":"1385_CR27","unstructured":"Twisk JWR. Applied multilevel analysis. A practical guide for medical researchers. 2nd revised ed. Cambridge University Press; 2013."},{"issue":"4","key":"1385_CR28","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2215\/CJN.08140910","volume":"6","author":"K Marfo","year":"2011","unstructured":"Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1385_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajt.14584","volume":"18","author":"R. A. Montgomery","year":"2018","unstructured":"Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: new approaches in prevention and management. Am J Transplant. 2018;(18 Suppl):3:3\u201317.","journal-title":"American Journal of Transplantation"},{"issue":"9","key":"1385_CR30","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of tocilizumab (anti-Interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant Glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381\u20139.","journal-title":"Am J Transplant"},{"issue":"1","key":"1385_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.transproceed.2011.12.006","volume":"44","author":"YA Hong","year":"2012","unstructured":"Hong YA, Kim HG, Choi SR, Sun IO, Park HS, Chung BH, et al. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant Proc. 2012;44(1):182\u20134.","journal-title":"Transplant Proc"},{"issue":"12","key":"1385_CR32","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/nep.12157","volume":"18","author":"MG Kim","year":"2013","unstructured":"Kim MG, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology (Carlton). 2013;18(12):820\u20136.","journal-title":"Nephrology (Carlton)"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1385-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1385-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T23:07:25Z","timestamp":1592003245000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1385-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,14]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1385-z","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,14]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was reviewed and approved by the Institutional Ethics Committee from the Erasmus MC, Rotterdam, The Netherlands. As this was a retrospective study, written consent to participate from the study subjects was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no conflicts of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"218"}}